New Danish biotech fund targeting 'approved' companies

A new Danish biotech fund prepares to invest in biotech companies with an FDA regulatory advantage. The ambition is to raise EUR 134m distributed between 20-40 companies, says experienced fund manager.

Peter Hildebrandt has more than 20 years' experience in biotech investments. | Photo: Privat

These are thriving times for Danish biotech businesses, triumphant Genmab standing out as the perhaps most remarkable example and Thursday's million dollar bid on Nueveolution proving the potential of many more companies.

All the more reason for Genmab and other global biotech companies to prepare themselves for a new Danish fund that has recently seen the light of day.

Read the whole article

Get 14 days free access.

No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from AMWatch

PFA says three big changes will bring better returns

To get returns on the same level as other pension firms, PFA has made three big changes to its portfolio, including taking on more risk, says the firm, which doesn't fear a backlash from this year's predicted unsteady market.

Further reading

Related articles

Latest news


Latest news from FinansWatch (dk)

Latest news from EnergyWatch

Latest news from ShippingWatch